This Express Update has been issued following the approval of rucaparib as a first-line PARPi maintenance option in EOC, and mirvetuximab soravtansine (MIRV) for recurrent, FRα-high EOC after 1-3 prior therapies and a platinum-free interval of <6 months. Included are updated treatment algorithms to support personalised therapy in newly diagnosed and recurrent EOC.
